Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

By: Immix Biopharma, Inc. via GlobeNewswire

June 20, 2023 at 09:45 AM EDT

Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin Pharmaceutical
Mr. Cooper is a former independent director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9 billion in 2022 and Tobira Therapeutics, acquired by Allergan (now AbbVie) for $1.7 billion in 2016

LOS ANGELES, June 20, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Jeffrey H. Cooper, former Chief Financial Officer of BioMarin Pharmaceutical Inc., has been appointed to the Company’s Board of Directors. Mr. Cooper brings significant leadership in finance, accounting, strategy, and mergers & acquisitions to Nexcella.

After joining BioMarin in 2003, Mr. Cooper held positions of increasing responsibility including Senior Vice President and Chief Financial Officer from 2007 until 2012. In addition to his experience at BioMarin, Mr. Cooper has served as an independent director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9 billion in 2022; and Tobira Therapeutics, acquired by Allergan (now AbbVie) for $1.7 billion in 2016.

“We are thrilled to have Mr. Cooper join the Nexcella Board of Directors. He possesses a wealth of experience as the CFO of BioMarin and board member of other biotechnology firms which have been acquired,” said Ilya Rachman, MD, Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “Mr. Cooper’s 30 years of deep experience in finance and capital markets of pharmaceutical organizations will be an invaluable as we advance NXC-201 towards US clinical trials and global applications for regulatory approvals. We look forward to his contribution to our mission.”

“My decades of experience as a CFO and audit chair in the pharmaceutical industry are a natural fit for Nexcella to further enable bringing much needed cell therapies to patients,” said Mr. Cooper. “I look forward to working with the Nexcella team to advance its important technology to the next stage.”

During his career, Mr. Cooper served as Chief Financial Officer of KaloBios Pharmaceuticals, Inc.; Vice President of Finance at Matrix Pharmaceuticals; Corporate Controller at Foundation Health Systems; and Director of Business Analysis at Syntex Corporation. Mr. Cooper received a B.A. from the University of California, Los Angeles and an M.B.A. from Santa Clara University. He was a Certified Public Accountant (inactive status) in the state of California through 2021.

About Nexcella, Inc.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc (Nasdaq:IMMX), is a Los Angeles, CA based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our lead candidate, next generation BCMA-targeted CAR-T NXC-201 for multiple myeloma and AL amyloidosis has produced 92% and 100% response rates in each indication, respectively, as of February 9, 2023 across 58 patients. We believe NXC-201 has potential to be the world’s first outpatient CAR-T. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201 in multiple myeloma and AL Amyloidosis, which we believe could be the world’s first out-patient CAR-T. Our lead TSTx asset IMX-110, currently in Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1 antibody tislelizumab, holds Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA. ImmixBio subsidiary Nexcella, Inc develops CAR-T NXC-201 for multiple myeloma and AL amyloidosis, with 92% and 100% response rates in each indication, respectively, as of February 9, 2023, currently being trialed in NEXICART-1. Learn more at www.immixbio.com.

Forward Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Immix Biopharma, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements.

Contacts

Stern Investor Relations
Alex Lobo
Managing Director
Alex.lobo@sternir.com

Company Contact

irteam@immixbio.com